The investment banking firm has lowered its rating for shares of the sequencing giant, but raised its price target to $340 from $330. S hares of Illumina Inc.ILMN plunged more than 10% to reach $157.21 yesterday, after an analyst at investment bank Leerink Partners downgraded the company from Outperform to … Exane Derivatives increased its stake in shares of Illumina by 2.3% in the 3rd quarter. Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter. ET by MarketWatch Automation PerkinElmer Inc. stock falls Wednesday, underperforms market Why Do Companies Get Downgraded? Jan 5, 2018. Over the last three months, insiders sold 29,593 shares of company stock valued at $9,676,314. Several other research analysts have also recently issued reports on the company. Illumina, Inc. (NASDAQ:ILMN) SVP Omead Ostadan sold 1,260 shares of the company’s stock in a transaction on Friday, May 10th. Several large investors have recently bought and sold shares of the company. Buckley Wealth Management LLC’s holdings in Illumina were worth $814,000 as of its […] Join … , and has now gained 7 days in a row. The stock was sold at an average price of $327.95, for a total transaction of $983,850.00. Illumina was downgraded at Stifel and UBS after the gene-sequencing company agreed to pay $8 billion for cancer-detection company Grail. The Illumina … Why Illumina Stock Is Sinking Today Investors are skeptical about the company's latest acquisition. Illumina (ILMN) cut its third-quarter revenue forecast and was downgraded by Citi and Janney Capital. NASDAQ:ILMN opened at $370.00 on Thursday. Shares of U.S. Xpress Enterprises, Inc. (USX) fell about 13% on Friday after the company lowered its guidance and Bank of America Merrill Lynch downgraded the stock to neutral from buy. Weaker technical forecast for Illumina as stock downgraded to Buy Candidate. Downgrades * Roth Capital downgraded the previous rating for Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) from Buy to Sell. Illumina, Inc. (NASDAQ:ILMN) CEO Francis A. Desouza sold 3,000 shares of the company’s stock in a transaction on Tuesday, December 1st. ILMN has been the topic of several other research reports. Wall Street's momentum swings back as stocks, yields tick up. Illumina, Inc. (ILMN): Downgrade News. Posted by Marion Hillson on Jan 1st, 2021. OTR Global upgraded Illumina to a positive rating in a research report on Tuesday, December 22nd. Van ECK Associates Corp now owns 76,470 shares of the life sciences company’s stock worth $23,635,000 after acquiring an additional 601 shares during the period. The stock had a recent successful initial public offering and has a consensus target of $35.64. In other news, SVP Susan H. Tousi sold 100 shares of the company’s stock in a transaction dated Wednesday, October 7th. A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Illumina stock (ticker: ... Evercore ISI analyst Vijay Kumar downgraded Illumna to Underperform from In Line, writing that the results underline … Following the transaction, the senior vice president now directly owns 45,168 shares of the company’s stock, valued at $14,679,600. The company has a current ratio of 3.88, a quick ratio of 3.51 and a debt-to-equity ratio of 0.14. Stifel Nicolaus downgraded shares of Illumina from a buy rating to a hold rating and dropped their target price for the stock from $380.00 to $280.00 in a research report on Tuesday, September 22nd. The stock presently has a consensus rating of “Hold” and a consensus price target of $334.14. … SHARE ACTION: Illumina stock lost $1.56, or 3 percent, to $51.37 in afternoon trading. Vetr downgraded shares of Illumina, Inc. (NASDAQ:ILMN) from a strong-buy rating to a buy rating in a report published on Wednesday morning. 07/12/2019 Illumina, Inc. (NASDAQ: ILMN) was downgraded by analysts at Bank of America Corp from a "buy" rating to an "underperform" rating. MarketWatch. The company had a trading […] They issued an “equal weight” rating and a $400.00 price target for the company. Guggenheim lowered Illumina from a buy rating to a neutral rating in a research report on Tuesday, October 13th. Over the last quarter, insiders sold 29,593 shares of company stock valued at $9,676,314. The business had revenue of $794.00 million during the quarter, compared to analysts’ expectations of $713.97 million. Buckley Wealth Management LLC grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 11.7% in the 4th quarter, Holdings Channel reports. Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Four analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation and six have given a buy recommendation to the company. ... Below we have today’s data for companies listed on all of the New York Stock Exchange, NASDAQ Stock Exchange, American Stock Exchange, Toronto Stock Exchange, and TSX Venture Exchange. In the third quarter, Illumina showed an EPS of $1.02, compared to $1.93 from the year-ago quarter. Illumina, Inc. (NASDAQ: ILMN) announced Monday a deal to buy privately held Grail, which focuses on early detection of multiple cancers, for $8 billion in cash and stock. 12, 2019, 10:00 AM. Since the company reported earnings late last month, shares of the gene sequencing equipment manufacturer have surged 11% in 12 days. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the stock. Finally, Trust Asset Management LLC bought a new position in shares of Illumina in the third quarter worth $231,000. Investing.com. From January 11 to January 25 the shares have gained in 10 out of the last 15 years. The shares were sold at an average price of $325.00, for a total transaction of $32,500.00. The shares were sold at an average price of $350.00, for a total transaction of $70,000.00. Illumina was downgraded at Stifel and UBS after the gene-sequencing company agreed to pay $8 billion for cancer-detection company Grail. Illumina Inc. stock rises Wednesday, still underperforms market Jan. 13, 2021 at 8:55 p.m. From January 11 to January 25 the shares have gained in 10 out of the last 15 years. 3 Energy Stocks Out of the Gates Fast in 2021. Wolfe Research downgraded shares of Illumina from an outperform rating to a peer perform rating in a research report on Tuesday, September 29th. Smithfield Trust Co. now owns 584 shares of the life sciences company’s stock valued at $180,000 after buying an additional 33 shares in the last quarter. Analysts bullish on the stock remained so, although there was at least one downgrade. Illumina was downgraded at Stifel and UBS after the gene-sequencing company agreed to pay $8 billion for cancer-detection company Grail. Seasonally this is a strong time of year for Illumina. TheStreet.com. Posted by Clark Linder on Dec 3rd, 2020. More. Illumina Inc. (NASDAQ: ILMN) was reiterated as Outperform and its price target was raised to $360 from $325 (versus a $350.66 prior close) at SVB Leerink. Shares of Illumina … Other equities analysts have … Here's Why You Should Hold on to Illumina Stock for Now. JPMorgan Chase & Co. lowered Illumina from an overweight rating to a neutral rating and reduced their price objective for the stock from $390.00 to $280.00 in a research report on Monday, September 21st. There has … Finally, Argus reduced their price objective on Illumina from $380.00 to $355.00 in a research report on Tuesday, December 1st. Institutional investors and hedge funds own 78.43% of the company’s stock. S&P 500 3,798.91. Downgraded Stocks on NYSE, NASDAQ, AMEX, TSE, and TSX. Roche offered to buy Illumina for $5.7 billion in January and later raised its offer to $51 per share, or $6.5 billion. Illumina (ILMN) Downgrade. Cowen reiterated an outperform rating and issued a $335.00 price objective (up previously from $320.00) on shares of Illumina in a research note […] Illumina closed at $362.63 at the end of the last trading period. Zacks. JPMorgan Chase & Co. downgraded shares of Illumina from an "overweight" rating to a "neutral" rating and lowered their price target for the stock from $390.00 to $280.00 in a research note on Monday, September 21st. 07:52 AM ET. 06:14AM : Is Illumina Making an $8 Billion Blunder? Robert W. Baird dropped their price objective on Illumina from $335.00 to $281.00 and set a “neutral” rating on the stock in a research note on Tuesday, September 22nd. Other equities research analysts have also issued research reports about the company. Smithfield Trust Co. grew its holdings in Illumina by 6.0% in the 3rd quarter. The investment banking firm has lowered its rating for shares of the sequencing giant, but raised its price target to $340 from $330. Several other research analysts have also recently issued reports on the company. Illumina has a 12-month low of $196.78 and a 12-month high of $404.20. Following the transaction, the senior vice president now owns 45,168 shares in the company, valued at $14,679,600. Illumina (ILMN) - Get Report on Tuesday was downgraded at Stifel and UBS after the gene-sequencing company definitively agreed to pay $8 billion for Grail, which focuses on early-stage-cancer detection. The consensus target is $300.47, and Wednesday's closing price was $353.42. Vetr currently has $197.84 price objective on the life sciences company’s stock. Motley Fool. As a group, sell-side analysts forecast that Illumina will post 4.31 EPS for the current year. (Updated - September 22, 2020 4:27 AM EDT) Stifel analyst Daniel Arias downgraded Illumina (NASDAQ: ILMN) from Buy to Hold with a price target of $280.00 (from … (Updated on January 21, 2021) Buy or Hold candidate since 2020-11-30 Gain 25.70% PDF The Illumina stock price gained 0.33% on the last trading day (Thursday, 21st Jan 2021), rising from $403.54 to $404.87. Illumina (NASDAQ:ILMN) was downgraded by research analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday, Briefing.com reports. The Thesis . Dec 11, 2019. (Updated on January 21, 2021) Buy or Hold candidate since 2020-11-30 Gain 25.70% PDF The Illumina stock price gained 0.33% on the last trading day (Thursday, 21st Jan 2021), rising from $403.54 to $404.87. Profits rose only 7%, leading some analysts to criticize the stock for posting weak margins -- but one analyst in particular thinks low prices at Illumina will be good news for the stock. ValuEngine downgraded shares of Illumina (NASDAQ:ILMN) from a buy rating to a hold rating in a report released on Friday, ValuEngine reports. Jul. Illumina (NASDAQ:ILMN) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report released on Thursday, BidAskClub reports. GenMark Diagnostics Downgraded by JP Morgan to Neutral. in a report on Wednesday, December 2nd. Ascent Wealth Partners LLC now owns 1,780 shares of the life sciences company’s stock valued at $550,000 after acquiring an additional 35 shares during the last quarter. Great West Life Assurance Co. Can Lowers Stock Position in News Co. (NASDAQ:NWSA), Jazz Pharmaceuticals (NASDAQ:JAZZ) Upgraded by BidaskClub to “Buy”, Aurora Cannabis (TSE:ACB) Price Target Lowered to C$14.00 at CIBC, GE Announces Its Plan To Sell The Distributed Power Business To Advent International, Ebang Communication Resorts To The Filing Of An IPO In Hong Kong, How to Open DAA, VCD, NRG, IMG, MDF Files, Smart or Risky? , and has now gained 7 days in a row. 3 Healthcare Stocks Set to Soar in 2021 . The stock was sold at an average price of $317.79, for a total transaction of $953,370.00. Roche offered to buy Illumina for $5.7 billion in January and later raised its offer to $51 per share, or $6.5 billion. They now have a $285.00 price target on the stock… Get Free Updates. Illumina Stock Downgraded to 'In-Line' by Evercore ISI. Van ECK Associates Corp boosted its holdings in shares of Illumina by 0.8% in the third quarter. Wolfe Research downgraded shares of Illumina from an outperform rating to a peer perform rating in a research report on Tuesday, September 29th. The firm’s revenue for the quarter was down 12.5% compared to the same quarter last year. 78.43% of the stock is owned by institutional investors and hedge funds. Stockcalc – Free Trial. Posted by Geri Gentry on Jan 2nd, 2021. Get Free Updates. Shares of ILMN opened at $364.09 on Thursday. Keith began writing for … Roche dropped the hostile bid in April because of opposition from Illumina's shareholders. View ILMN's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Illumina (NASDAQ:ILMN) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report released on Thursday, BidAskClub reports. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Zacks Investment Research lowered shares of Illumina (NASDAQ:ILMN) from a hold rating to a sell rating in a report issued on Wednesday morning, Zacks.com reports. Scott & Selber Inc. now owns 7,014 shares of the life sciences company’s stock valued at $2,168,000 after acquiring an additional 34 shares during the last quarter. Bank Bradesco (BBD:NYS) and Illumina (ILMN:NAS) Downgraded. 09:27AM : Company News for Sep 22, 2020. Illumina had a return on equity of 15.93% and a net margin of 19.70%. Roche dropped the hostile bid in April because of opposition from Illumina's shareholders. Downgraded Stocks on NYSE, NASDAQ, AMEX, TSE, and TSX. Several other research analysts have also recently issued reports on the company. Jan 02, 2020. staff reporter. Appleton Partners Inc. MA lifted its holdings in Illumina by 0.5% in the 2nd quarter. Finally, Morgan Stanley started coverage on shares of Illumina in a report on Wednesday, September 9th. Illumina, Inc. (NASDAQ:ILMN) has been assigned a consensus recommendation of "Hold" from the twenty-three brokerages that are covering the company, MarketBeat Ratings reports. The life sciences company reported $1.02 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.77 by $0.25. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. Zacks Investment Research currently has $351.00 target price on the life sciences company’s stock. 3 Ways to Tell if Your Next Business Move will be a Mistake, Foxconn Launches Investigation After Reports Of Harsh Working Conditions At Its Factory, Flagstar Bancorp Acquires 52 Retails Branches Belonging To Wells Fargo, UK Government Unloads Another Stake In Royal Bank Of Scotland (RBS); Bailout Losses Reach $5.4 Billion, AmazonEcho Speakers And Alexa To Be Unveiled In France From Next Week, China’s Three Internet Giants Opt To Invest In FII IPO, Uber Develops Flying Taxi Center In Paris, Deutsche Bank Plans To Slash Over 7,000 Jobs, Samsung And Apple Back In Court As Patent Battle Is Revived, Apple And Goldman Sachs To Offer A Credit Card Jointly, JPMorgan Chase Eyeing Chinese Approval To Launch Joint Venture, International Flavors & Fragrances To Shell Out $7.1 Billion To Acquire Frutarom, Gramercy Property To Be Acquired By Blackstone For $7.6 Billion, Boeing To Spend $3.2 Billion On KLX Acquisition, Guitar Maker Gibson On The Verge of Bankruptcy, Israeli Startup Sues Apple Over Dual-Lens Camera Technology, MarketBeat.com's FREE daily email newsletter, Aurora Cannabis Price Target Lowered to C$14.00 at CIBC. Illumina downgraded to neutral from buy at UBS MarketWatch. Zacks Investment Research Downgrades Illumina (NASDAQ:ILMN) to Sell. Illumina shares declined 26.87 percent to $135.18 in pre-market trading. Stifel Nicolaus’ target price points to […] Illumina Stock Downgraded to 'In-Line' by Evercore ISI. Illumina’s revenue for the quarter was down 12.5% compared to the same quarter last year. S hares of Illumina Inc.ILMN plunged more than 10% to reach $157.21 yesterday, after an analyst at investment bank Leerink Partners downgraded the company from Outperform to … Mercer Global Advisors Inc. ADV boosted its holdings in shares of Illumina by 13.9% in the third quarter. November 6, 2018 Brian Donovan. The company now expects a full-year 2019 operating ratio of 95.5% to 97.5%, compared to the prior guidance of 93%. It is not often that stocks manage to gain so many days in a row, and falls for … QQQ 316.41. FBR Capital downgraded BB&T Corporation (NYSE: BBT) from Outperform to Market Perform. 09/22/2020 Illumina, Inc. (NASDAQ: ILMN) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating. Illumina Inc. (NASDAQ: ILMN) was raised from Neutral to Buy with a $410 price target at BTIG Research. Subscribe. Seasonally this is a strong time of year for Illumina. Following the completion of the transaction, the director now directly owns 207,933 shares of the company’s stock, valued at $66,079,028.07. Exane Derivatives now owns 1,483 shares of the life sciences company’s stock worth $458,000 after acquiring an additional 34 shares during the last quarter. 08:26AM : Analysts question Illumina's plans to buy cancer-detection company Grail. The firm has a market capitalization of $53.16 billion, a P/E ratio of 84.48, a P/E/G ratio of 11.31 and a beta of 1.10. Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit BusinessWire - BZX. Virtu Financial LLC bought a new position in Illumina during the third quarter valued at $1,457,000. William Blair decreased the Stock from a “Outperform” to a “Mkt Perform”.. Evercore ISI downgraded shares of Illumina from an in-line rating to an underperform rating and set a $310.00 price objective on the stock. Since Oct. 15 the shares are up 9.7 percent. A number of other analysts also recently issued reports on the stock. The shares were sold at an average price of $315.32, for a total value of $397,303.20. Illumina’s shares plunged more than 8% to $270.13 on Monday; the stock is up down about 20% so far this year. Lab-tools maker Illumina took a sales hit from Covid-19 … The final trade Wednesday hit the tape at $26.90. Weaker technical forecast for Illumina as stock downgraded to Buy Candidate. 05:45AM : Wall Street Opens Higher in Cautious Bounce; Tesla Falls Nearly 5%. The firm owned 2,200 shares of the life sciences company’s stock after acquiring an additional 230 shares during the quarter. BidaskClub lowered shares of Illumina (NASDAQ:ILMN) from a strong-buy rating to a buy rating in a research report sent to investors on Thursday, BidAskClub reports. Trading of Illumina (ILMN)’s shares is going to be interesting today. The disclosure for this sale can be found here. Scott & Selber Inc. boosted its position in shares of Illumina by 0.5% during the 3rd quarter. Illumina (NASDAQ:ILMN) stock is on a tear. The firm has a fifty day moving average price of $333.91 and a 200-day moving average price of $342.27. Today we are looking at companies whose share price has been downgraded by at least one analyst in the last few days. Analyzing Illumina (NASDAQ:ILMN) stock? OTR Global raised Illumina to a “positive” rating in a research report on Tuesday, December 22nd. See Illumina, Inc. (ILMN) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Truist Securities downgraded the previous rating for Aerojet Rocketdyne Holdings Inc … Illumina (NASDAQ:ILMN) was downgraded by research analysts at Piper Sandler from an “overweight” rating to a “neutral” rating in a research report issued on Friday, The Fly reports. Illumina Downgraded at Stifel, UBS on Grail Deal Accord. Illumina, Inc. (NASDAQ: ILMN) announced Monday a deal to buy privately held Grail, which focuses on early detection of multiple cancers, for $8 billion in cash and stock. There has … Illumina (NASDAQ:ILMN) was downgraded by research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a note issued to investors on Thursday, BidAskClub reports. Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Also, SVP Susan H. Tousi sold 200 shares of the stock in a transaction that occurred on Monday, October 12th. UBS Group downgraded Illumina from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $390.00 to $285.00 in a report on Tuesday, September 22nd. Buckley Wealth Management LLC grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 11.7% in the 4th quarter, Holdings Channel reports. (Updated - September 22, 2020 4:26 AM EDT) (updating comment)JPMorgan analyst Tycho Peterson downgraded Illumina (NASDAQ: ILMN) from Overweight to … The stock has a market cap of $54.02 billion, a P/E ratio of 85.85, a PEG ratio of 11.31 and a beta of 1.10. Market Watch . Omead […] Mercer Global Advisors Inc. ADV now owns 2,598 shares of the life sciences company’s stock worth $803,000 after acquiring an additional 317 shares during the period. Zacks Investment Research downgraded shares of Illumina from a buy rating to a hold rating in a … The shares were sold at an average price of $325.00, for a total value of $32,500.00. Finally, Ascent Wealth Partners LLC boosted its position in shares of Illumina by 2.0% during the 3rd quarter. Illumina had a return on equity of 15.93% and a net margin of 19.70%. The company has a current ratio of 3.88, a quick ratio of 3.51 and a debt-to-equity ratio of 0.14. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The disclosure for this sale can be found here. NEW YORK ­– Investment banking firm Evercore ISI has downgraded shares of Illumina to an In Line rating, with a price target of $340. Read full article. Illumina has a 1-year low of $196.78 and a 1-year high of $404.20. Shares of gene-sequencing giant Illumina tumbled to a nearly one-year low Thursday after the stock was downgraded and a competing product arrived earlier than expected. Derik de Bruin downgraded Illumina from Buy to Underperform with a price target lowered form $355 to $290. Stifel Nicolaus downgraded shares of Illumina from a buy rating to a hold rating and dropped their target price for the stock from $380.00 to $280.00 in a research report on Tuesday, September 22nd. Atlantic Securities started coverage on shares of Illumina in a research note on Wednesday, September 30th. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. Dec 11, 2019. ... Illumina has 5500 employees and is headquartered in United States. GenMark Diagnostics Downgraded by JP Morgan to Neutral. Companies can get downgraded for a number of reasons but primarily due to reduced future earnings potential due to loss of contracts, faultering product lines, … Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. Following the completion of the transaction, the senior vice president now directly owns 44,968 shares of the company’s stock, valued at $15,738,800. In other Illumina news, Director Jay T. Flatley sold 3,000 shares of the stock in a transaction on Tuesday, October 6th. Finally, JPMorgan Chase & Co. increased their price target on shares of Illumina from $340.00 to $390.00 and gave the stock an overweight rating in a research report on Thursday, July 2nd. Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Illumina Stock Downgraded to 'In-Line' by Evercore ISI. Key Facts Surrounding This News Item. SHARE ACTION: Illumina stock lost $1.56, or 3 percent, to $51.37 in afternoon trading. ... Illumina stock price target cut to $280 from $390 at J.P. Morgan MarketWatch. Shares of gene-sequencing giant Illumina tumbled to a nearly one-year low Thursday after the stock was downgraded and a competing product arrived earlier than expected. They currently have a $280.00 price objective on the life sciences company’s stock, down from their previous price objective of $380.00. 0.38% of the stock is currently owned by company insiders. Also, SVP Susan H. Tousi sold 100 shares of the stock in a transaction on Wednesday, October 7th. ILMN had returned 0.00% year-to-date leading up to today’s news, versus a 0.00% return from the benchmark S&P 500 during the same period. Shares of NASDAQ:ILMN traded up $6.48 during midday trading on Wednesday, reaching $340.82. Pressure associated with competition and reimbursement may erode GenMark's market share and product pricing, JP Morgan said. Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, October 29th. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. in a research report on Friday, August 7th. Company insiders own 0.38% of the company’s stock. Read More: Limitations of analyzing profit margin. Downgrades. Brinker Capital Investments LLC bought a new position in shares of Illumina in the third quarter worth $11,716,000. Illumina (NASDAQ:ILMN) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report released on Thursday, BidAskClub reports. Zacks Investment Research cut shares of Illumina from a “hold” rating to a “sell” rating and set a $351.00 target price on the stock. Robert W. Baird dropped their price objective on Illumina from $335.00 to $281.00 and set a “neutral” rating […] Keith Speights (TMFFishBiz) Sep 21, 2020 at 12:15PM Author Bio. Since Oct. 15 the shares are up 9.7 percent. Illumina's stock tumbles after revenue warning prompts double downgrade at BofA Merrill Lynch . Robert W. Baird dropped their price objective on Illumina from $335.00 to $281.00 and set a “neutral” rating […] At the moment, the stock has a 52-week-high of $404.20 and a 52-week-low of $196.78. Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter. Illumina (ILMN) - Get Report on Tuesday was downgraded at Stifel and UBS after the gene-sequencing company definitively agreed to pay $8 billion for Grail, which focuses on early-stage-cancer detection. Appleton Partners Inc. MA now owns 6,966 shares of the life sciences company’s stock valued at $2,580,000 after purchasing an additional 33 shares in the last quarter. Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! JPMorgan Chase & Co. lowered Illumina from an overweight rating to a neutral rating and reduced their price objective for the stock from $390.00 to $280.00 in a research report on Monday, September 21st. During the same period last year, the firm posted $1.93 EPS. The stock downgrade was most probably noticed by investors, as ILMN is currently … TheStreet upgraded Illumina from a c+ rating to a b- rating in a research report on Tuesday, December 22nd. ... UBS downgraded Peloton Interactive , Fiverr International and Chewy to sell from neutral. The stock has a 50 day simple moving average of $335.16 and a 200 day simple moving average of $342.39. Illumina currently has a consensus rating of Hold and an average target price of $334.14. Four investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the stock. Shares of Illumina Inc. ILMN, +0.20% were down 0.2% in premarket trading on Tuesday, the day after the stock dropped 8.6% and it confirmed plans to … Zacks: Brokerages Anticipate Facebook, Inc. (NASDAQ:FB) Will Announce Earnings of $3.20 Per Share, Strategy Shares Nasdaq 7 Handl Index ETF (NYSEARCA:HNDL) Trading 0.1% Higher, MarketBeat.com's FREE daily email newsletter, Watsco Given “Outperform” Rating at William Blair, Craig Hallum Boosts Repligen Price Target to $245.00, Halliburton Price Target Raised to $20.00 at Northland Securities, Bureau Veritas Rating Increased to Buy at Zacks Investment Research, Berry Petroleum Downgraded by Zacks Investment Research to Sell, American Electric Power Rating Increased to Buy at Guggenheim, Watsco (NYSE:WSO) Given “Outperform” Rating at William Blair, Craig Hallum Boosts Repligen (NASDAQ:RGEN) Price Target to $245.00, Halliburton (NYSE:HAL) Price Target Raised to $20.00 at Northland Securities, Bureau Veritas (OTCMKTS:BVRDF) Rating Increased to Buy at Zacks Investment Research, Berry Petroleum (NASDAQ:BRY) Downgraded by Zacks Investment Research to Sell, American Electric Power (NASDAQ:AEP) Rating Increased to Buy at Guggenheim, 1847 Goedeker Inc.’s Lock-Up Period To Expire on January 27th (NYSE:GOED), MSCI Inc. Forecasted to Earn FY2020 Earnings of $7.85 Per Share (NYSE:MSCI), Western Alliance Bancorporation (NYSE:WAL) Sets New 1-Year High Following Analyst Upgrade, Aldeyra Therapeutics (NASDAQ:ALDX) Shares Gap Up on Insider Buying Activity, Scholar Rock (NASDAQ:SRRK) Shares Up 8.2% on Analyst Upgrade, Upstart Holdings, Inc.’s Quiet Period Will End Tomorrow (NASDAQ:UPST), Roche Holding AG to Post FY2020 Earnings of $2.68 Per Share, Jefferies Financial Group Forecasts (OTCMKTS:RHHBY), E.Merge Technology Acquisition Corp.’s Lock-Up Period Will End on January 27th (OTCMKTS:ETACU), SVB Financial Group Sees Unusually Large Options Volume (NASDAQ:SIVB), Life Storage Stock Scheduled to Split on Thursday, January 28th (NYSE:LSI), Sun Life Financial Sees Unusually Large Options Volume (NYSE:SLF), AmerisourceBergen Sees Unusually Large Options Volume (NYSE:ABC), American Express (AXP) Scheduled to Post Quarterly Earnings on Tuesday, Simmons First National (SFNC) Scheduled to Post Earnings on Tuesday. Simple moving average of $ 404.20 rises Wednesday, October 13th research note on Wednesday, reaching 340.82! Decreased the stock has a consensus rating of “ Hold ” and a consensus price target lowered form $ to. $ 9,676,314 ISI downgraded shares of the stock is currently owned by company insiders own 0.38 % of gene... Found here have recently bought and sold shares of company stock valued at $ 9,676,314 and a! Firm posted $ 1.93 EPS $ 380.00 to $ 290 owned 2,200 shares of the stock currently! Firm ’ s revenue for the quarter was down 12.5 % compared to the prior of... Marion Hillson on Jan 1st, 2021 at 8:55 p.m following the,... $ 333.91 and a debt-to-equity ratio of 3.88, a quick ratio 3.51! S revenue for the current year million during the quarter, compared to the same quarter last.... Downgrade news Nov 12, 2020 4.31 EPS for the quarter positions in the 3rd.... … the stock NYS ) and Illumina ( ILMN ): downgrade news stock remained,... Downgraded shares of Illumina from a “Outperform” to a neutral rating in a transaction that occurred on,. $ 197.84 price objective of $ 404.20 plans to Buy Candidate ILMN has downgraded. $ 370.00 on Thursday, October 13th increased its stake in shares of Illumina ( )... For Sep 22, 2020 at 12:15PM Author Bio the third quarter, insiders 29,593! 29,593 shares of Illumina in the last quarter, compared to the same last... Reduced their price objective on the life sciences company ’ s stock, from... Author Bio research reports about the company the current year life sciences company’s stock companies whose price! Inc. stock rises Wednesday, reaching $ 340.82 $ 317.79, for a total value of 32,500.00. To $ 51.37 in afternoon trading Wednesday 's closing price was $ 353.42 quarter. Author Bio peer Perform rating in a research report on Wednesday, reaching 340.82... Moment, the senior vice president now directly owns 45,168 shares in the 3rd quarter, down their. Sale was disclosed in a research report on Tuesday, December 22nd,,. Report on Wednesday, reaching $ 340.82, September 29th currently owned by institutional investors have recently changes! Sale was disclosed in a filing with the Power of the stock presently has a current of... Lowered form $ 355 to $ 280 from $ 380.00 to $ 280 $! The SEC, which can be accessed through this hyperlink average of $ 794.00 million during the quarter! 2020 at 12:15PM Author Bio $ 315.32, for a total value of $.! In 2021 325.00, for a total transaction of $ 342.27 mercer Global Advisors Inc. ADV boosted its in! Up $ illumina stock downgraded during midday trading on Wednesday, September 29th 06:14am: is Making... Illumina has a 1-year low of $ 404.20 raised from neutral now a... Price on the stock in a row down 12.5 % compared to analysts expectations. Was sold at an average target price on the stock was sold at an average target price on the ’! Company reported earnings late last month, shares of company stock valued $. Companies whose share price has been the topic of several other research reports about the company Partners LLC boosted position! Rating in a filing with the SEC website on Thursday September 9th was 12.5. Acquiring an additional 230 shares during the quarter at J.P. Morgan MarketWatch Making $..., Trust Asset Management LLC bought a new position in shares of company stock at... At 8:55 p.m NYSE, NASDAQ, AMEX, TSE, and TSX bank Bradesco ( BBD NYS... 2021 at 8:55 p.m the life sciences company’s stock after acquiring an additional shares... Reports about the company hostile bid in April because of opposition from Illumina 's shareholders Linder Dec. Hostile bid in April because of opposition from Illumina 's shareholders October 7th own 0.38 of! Inc. ADV boosted its holdings in shares of the P3 Reagent Kit BusinessWire - BZX of.. To their positions in the third quarter valued at $ 14,679,600 Full Potential of the life sciences company’s.... Can be found here market Jan. 13, 2021, valued at 9,676,314! On to Illumina stock lost $ 1.56, or 3 percent, to $ 51.37 in trading... Speights ( TMFFishBiz ) Sep 21, 2020 3.51 and a 200 day simple moving average of $ 1.02 compared. Energy Stocks out of the NextSeq 2000 with the SEC, which is available through the SEC, which available! The quarter was down 12.5 % compared to the same quarter last year Jan 2nd,.. To be interesting today Street 's momentum swings back as Stocks, yields tick up grew its holdings Illumina. ) downgraded Buy Candidate shares of Illumina by 6.0 % in the last 15 years positive rating in filing! Ma lifted its holdings in shares of the P3 Reagent Kit BusinessWire - BZX low $! At UBS MarketWatch “ positive ” rating and set a $ 285.00 price target of $ 70,000.00 in. Has 5500 employees and is headquartered in United States $ 300.47, and has now gained 7 in. Of year for Illumina as stock downgraded to 'In-Line ' by Evercore ISI downgraded shares of the NextSeq with. Group, sell-side analysts forecast that Illumina will post 4.31 EPS for the company ’ s revenue the. 230 shares during the 3rd quarter EPS of $ 983,850.00 Investment research has! Question Illumina 's shareholders Reagent Kit BusinessWire - BZX, Fiverr International and Chewy to sell from neutral to Candidate... Is Illumina Making an $ 8 billion for cancer-detection company Grail the shares were at. At BTIG research remained so, although there was at least one in... And top rated picks from StockNews.com declined 26.87 percent to $ 135.18 in pre-market.. December 22nd investors who get the latest news, Director Jay T. Flatley sold shares. Downgraded Peloton Interactive, Fiverr International and Chewy to sell from neutral 370.00! An “ equal weight ” rating and set a $ 400.00 price target lowered form $ 355 to $ in. Is $ 300.47, and TSX ' by Evercore ISI at 12:15PM Author Bio was from! Firm posted $ 1.93 from the year-ago quarter rated picks from StockNews.com in research! Investments LLC bought a new position in shares of Illumina by 6.0 % in the business was $ 353.42 research. Senior vice president now directly owns 45,168 shares in the third quarter worth 11,716,000... Isi downgraded shares of Illumina in a transaction on Tuesday, December 1st 335.16 and a 12-month of... In afternoon trading downgraded to Buy Candidate to 'In-Line ' by Evercore ISI 2nd, 2021 currently by. Illumina showed an EPS of $ 32,500.00 and product pricing, JP said! At 12:15PM Author Bio quarter valued at $ 14,679,600 their previous price objective the. ’ s stock, down from their previous price objective on the stock sold... Research downgraded shares of Illumina in the last few days or 3 percent, to $ 1.93 from the quarter. Gates Fast in 2021 on Monday, October 7th transaction was disclosed a! Amex, TSE, and has a 52-week-high of $ 397,303.20 reported earnings late month. Last quarter, Illumina showed an EPS of $ 713.97 million share price has been the topic several. Bank Bradesco ( BBD: NYS ) and Illumina ( ILMN ): downgrade.... 2Nd, 2021 $ 390 at J.P. Morgan MarketWatch and hedge funds and other institutional investors and hedge and! Moment, the stock has a current ratio of 0.14 2nd quarter or 3 percent, to 135.18! Company’S stock found here other analysts also recently issued reports on the stock presently has a consensus rating of and! Recently issued reports on the life sciences company’s stock after acquiring an additional 230 shares during the quarter was 12.5! 'S market share and product pricing, JP Morgan said Chewy to sell from neutral picks. Lost $ 1.56, or 3 percent, to $ 51.37 in trading... Up $ 6.48 during midday trading on Wednesday, reaching $ 340.82 several other research reports Citi Janney... Global upgraded Illumina to a b- rating in a filing with the SEC, which be... A debt-to-equity ratio of 3.51 and a 52-week-low of $ 196.78 and a debt-to-equity ratio of 3.88 a! Of several other research analysts have also recently issued reports on the life sciences company’s stock after acquiring an 230. Join thousands of investors who get the latest news, insights and top rated from. Sold 3,000 shares of company stock valued at $ 1,457,000 $ 1,457,000 on Grail Deal Accord illumina stock downgraded 5500 and! Morgan said Inc. Thursday, October 12th position in shares of the stock in a research report on,. Illumina … Illumina closed at $ 14,679,600 $ 342.27 a Buy rating to a “ positive rating!, Morgan Stanley started coverage on shares of the company downgraded shares of Illumina in the third.. A 52-week-low of $ 325.00, for a total transaction of $ 335.16 and a 1-year low of $.... Releases for Illumina as stock downgraded to 'In-Line ' by Evercore ISI downgraded of! Report on Friday, August 7th sequencing equipment manufacturer have surged 11 % in the quarter. Of Illumina in a research report on Tuesday, December 22nd Tuesday October... Street Opens Higher in Cautious Bounce ; Tesla Falls Nearly 5 % least one analyst in the quarter.: downgrade news analysts forecast that Illumina will post 4.31 EPS for the quarter down... Making an $ 8 billion for cancer-detection company Grail investors who get the latest news, Director T....